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Abstract  
Background: Unexpectedly high occurrence or recurrence rate of hepatocellular 
carcinoma (HCC) has been observed in patients with chronic hepatitis C receiving 
direct-acting antivirals (DAAs) therapy.  
Aims: We evaluated the predictive value of albumin-bilirubin (ALBI) score and 
immune-inflammation indicators to identify the risk of occurrence or recurrence of 
HCC in patients treated with DAAs in a real life setting. 
Methods: In this retrospective cohort study, we analysed data from 514 patients with 
cirrhosis who were prospectively enrolled for treatment with DAAs. We assessed 
baseline neutrophil to lymphocyte ratio (NLR), systemic immune-inflammation index 
(SII), platelet to lymphocyte ratio (PLR), aspartate aminotransferase-lymphocyte ratio 
(ALRI) index and ALBI score. 
Results: In patients with no history of HCC (N=416), increased AST, bilirubin, ALRI, 
and ALBI score, and decreased albumin and platelets were significantly associated with 
an increased risk of HCC development, at univariate analysis. At multivariate analysis, 
increase in ALBI grade (p = 0.038, HR: 2.35, 95% CI: 1.05–5.25) and decrease in 
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platelets (p = 0.048, HR: 0.92, 95% CI: 0.85–1.0) were independently associated with 
HCC development. In patients with previous HCC (N=98), adjusting for the time from 
HCC treatment, increased ALRI (p = 0.008, HR: 1.05, 95% CI: 1.01–1.09) was 
significantly associated with a risk of recurrence.  
Conclusion: ALBI score, platelet count and ALRI are promising, easy to perform and 
inexpensive tools for identifying patients with higher risk of HCC after treatment with 
DAAs. 
 
 
Abbreviations 
HCC:  hepatocellular carcinoma; DAA: direct-acting antivirals; HCV: hepatitis C virus; 
SVR: sustained virological response; AIFA: Italian Medicines Agency; CEUS: contrast-
enhanced ultrasonography; CT: computerized tomography; MRI: magnetic resonance 
imaging; RFA: radiofrequency ablation; TACE: trans-arterial chemoembolization; PEI: 
percutaneous ethanol injection; kPa: kilo Pascal; HBsAg: hepatitis B surface antigen; 
BMI: body mass index; SOF: sofosbuvir; SMV: simeprevir; RBV: ribavirin; DCV: 
daclatasvir; LDV: ledipasvir; AFP:α-fetoprotein; BCLC: Barcelona Clinic Liver 
Cancer; US: ultrasound. 
 
 
 
 
Keywords: albumin; bilirubin; ALRI; SII; NLR; PLR; interferon-free therapy; 
cirrhosis; cancer immunosurveillance.  
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1. Introduction 
Interferon(IFN)-free regimen using new direct acting antivirals (DAAs) has represented 
a turning point in the treatment of patients with chronic hepatitis C [1]. 
The impact of DAAs-based treatment on the development of hepatocellular carcinoma 
(HCC) in patients with cirrhosis has grown controversial due to potential clinical 
implications, particularly for HCC recurrence after a successful curative treatment. 
Some studies have recently reported an unexpectedly high HCC recurrence rate of 27-
29% among subjects treated with liver resection or ablation, who had received DAAs 
therapy [2-4]. However, similar results were not confirmed in other studies [5-9]. 
The mechanism that could explain such a high rate of tumor recurrence after DAAs 
treatment is one of the main topics of these studies. Microenvironment and viral-
induced inflammation are supposed to play a key role in chronic liver injury and tumor 
initiation [10]. However, the human immune system itself has also an anti-tumor 
function [11]. Overall, there is a complex yet fragile balance between the pro- and anti-
tumor functions of the immune system. Some studies have proposed that DAAs 
treatment could modify the natural killer function and the expression of IFN response 
genes [12,13]. 
Several inflammation prognostic scores, such as the systemic immune-inflammation 
index (SII), the neutrophil to lymphocyte ratio (NLR), the platelet to lymphocyte ratio 
(PLR) and the aspartate aminotransferase-lymphocyte ratio index (ALRI), have been 
developed to predict survival and recurrence in patients with HCC [14-23]. AC
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The albumin-bilirubin (ALBI) score was first proposed by Johnson et al. [24], with the 
aim to obviate the need of subjective variables, such as ascites and encephalopathy, in 
the Child-Pugh grading system, for liver function evaluation in HCC patients. 
The objective of this study was to evaluate the predictive value of ALBI score and 
immune-inflammation indicators to identify the risk of HCC occurrence or recurrence in 
patients treated with DAAs for chronic hepatitis C. 
 
2. Materials and Methods 
2.1Patient selection and treatment 
In this retrospective cohort study, we analysed data from all the consecutive HCV-
infected cirrhotic patients treated with DAAs in seven hepatology centers in the area of 
Bologna, Italy, between January 2015 and August 2016. Follow-up ended in January 
2017. Data were first retrieved from the electronic regional registry database 
(Piattaforma SOLE). All the additional data were obtained from the individual patient 
records. 
Eligibility for treating hepatitis C with DAAs was assessed for each patient following 
the priority criteria established by the national registry of the Italian Medicines Agency 
(AIFA). When possible, alternative treatment options were sought at the clinician’s 
discretion. 
Diagnosis of liver cirrhosis was established if at least one of the following was present: 
1) previous liver biopsy with stage 4 fibrosis with METAVIR score; 2) presence of 
esophageal and/or gastric varices at endoscopy; 3) liver stiffness higher than 12 kPa at 
transient elastography by FibroScan (Echo Sense, Paris, France) [25,26]. 
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Patients with previous liver transplantation or with treated HCC without radiological 
complete response before starting DAAs were excluded. 
The database included 688 patients treated with different regimens of DAAs (105 with 
and 563 without HCC history). Since our analysis was limited to patients with liver 
cirrhosis, 144 were excluded because of a F3 METAVIR score or a transient 
elastography result of less than 12 kPa. Further 10 patients (5 in each category) were not 
included in the analysis due to liver transplantation (Fig. 1). 
Before starting antiviral therapy, all patients with no HCC history underwent abdomen 
ultrasound (US). If a potential focal lesion was detected in the liver, the diagnostic 
work-up was completed with contrast-enhanced ultrasonography (CEUS), and a 
subsequent computerized tomography (CT) scan or magnetic resonance imaging (MRI) 
was performed to exclude the presence of HCC. All the patients with a history of HCC 
underwent ultrasound and CT scan or MRI to exclude recurrent HCC. 
All patients were followed-up after EOT. During follow-up, patients repeated US 
evaluation as recommended by the surveillance programme guidelines [27]; in case of 
suspicion of HCC development, CEUS/CT/MRI were carried out to determine the 
presence of HCC. 
Virological response to therapy was assessed by quantitative HCV-RNA determination, 
using real-time PCR with a limit of detection of 15 IU/ml. 
All blood values were obtained at baseline and at the end of the treatment.  
 
2.2 Statistical Analysis  
Data were summarized by mean ± standard deviation or median and minimum or 
maximum value for continuous variables, and by frequency and percentage for 
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categorical variables. Clinical characteristics between patients with and without a 
history of HCC were compared using the Chi-square test or the Fisher Exact test, when 
appropriate, for categorical variables and the Student-t test or the Wilcoxon rank-sum 
test, when appropriate, for continuous variables. 
With regard to the time to HCC detection (occurrence or recurrence), we performed 
distinct analyses for patients with or without a history of HCC. 
The Nelson-Aalen estimator was used to obtain cumulative hazard rates at specific 
follow-up time points within the two groups of patients (with and without a history of 
HCC). 
The median censoring time was computed as the median of the time points since the 
start of DAA treatment until death, last patient contact or the end of follow-up (censored 
times), that is, considering only patients not experiencing the event of interest and 
included in the two groups of patients. The median time to HCC was computed as the 
median of the time points since the start of DAA treatment to HCC occurrence, 
considering only patients experiencing the event of interest and included in the two 
groups of patients. Results are reported as point estimate and 95% confidence intervals 
(CIs) in round brackets. 
Kaplan-Meier curves were used to represent the time to HCC onset since the beginning 
of DAA treatment. Time was censored at the time of death, last patient contact or end of 
follow-up. Cox regression was used to evaluate the association between inflammation 
indices and other covariates and the time to HCC. When not specified, continuous 
covariates were included in the models as they were, that is, without dichotomization or 
categorization. For ease of interpretation, some of the reported hazard ratios (HRs) for 
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continuous covariates correspond to a 10-unit increase in the corresponding variable 
rather than a 1-unit increase. 
The underlying assumption of proportional hazard was tested on the basis of Schoenfeld 
residuals. 
Given the limited number of HCC events and thus the need for a more parsimonious 
model as well as the presence of correlation among variables, to specify the final Cox 
regression model we decided to focus our attention of the inflammation indices rather 
than their single components. Due to the presence of missing values for the continuous 
variables, multiple imputation using multivariate normal distribution with ten imputed 
datasets was performed [28]. 
NLR was computed as the ratio of the absolute neutrophil count to the absolute 
lymphocyte count, PLR as the ratio of absolute platelet count to the absolute 
lymphocyte count, SII as platelet count × neutrophil count/lymphocyte count, and ALRI 
as the ratio of aminotransferase to absolute lymphocyte count. ALBI was obtained 
through the following formula: (log10 bilirubin × 0.66) + (albumin × -0.085) where 
bilirubin is in µmol/L and albumin in g/L. PALBI was obtained using the following 
formula: (2.02 × log10 bilirubin) + [-0.37 × (log10 bilirubin)
2] + (-0.04 × albumin) + (-
3.48 × log10 platelets) + [1.01 × (log10 platelets)
2]. For patients with a history of HCC, 
the time from HCC treatment until start of DAA treatment was computed and 
categorized as follows: < 6 months, 6 - 12 months, 12 - 24 months, and ≥ 24 months. 
Exploratory analyses were performed to test for differences in the mean values of 
clinical parameters at three different time points (baseline, end-of-treatment, and at 12 
weeks of follow-up). An ANalysis Of VAriance (ANOVA) for repeated measurements 
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was used for this purpose with Bonferroni adjustment for post-hoc comparisons. The 
analysis was performed only on patients with data at all three time points. 
To evaluate the effect of changes in specific clinical parameters from the baseline to the 
end-of-treatment, Cox regression models were fitted including the absolute change (i.e. 
lymphocytes at the end-of-treatment minus lymphocytes at baseline) as covariate of 
interest and adjusting for the value of the clinical parameter at the baseline. This 
exploratory analysis was performed only on patients with data at both time points. 
A p-value less than 0.05 was considered statistically significant. Analyses were 
performed using STATA 14.0 (College Station, Texas, USA) and R version 3.4.0 
statistical software (package “rms” for drawing the nomogram). 
 
3. Results  
3.1 Patient characteristics 
We performed our analysis on the 514 consecutive patients with HCV-related liver 
cirrhosis treated with different DAA regimens between January 2015 and August 2016. 
We split the population into two groups for analysis: patients with history of HCC (98) 
and without (416).  
The median follow-up was 18.04 months (range 0.43–26.41) from the start of the 
treatment. The baseline characteristics of the two groups before starting DAA therapy 
are shown in Table 1. 
HCC was detected and confirmed by at least two independent imaging techniques, or 
biopsy, in 30 out of 98 patients (30.6%) with a history of HCC, and in 29 out of 416 
patients (7.0%) without a history of HCC. 
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In patients with a history of HCC the cumulative hazards of HCC recurrence at 6, 12, 
and 18 months were 0.074 (95% CI: 0.035-0.156), 0.261 (95% CI: 0.172-0.079) and 
0.380 (95% CI: 0.262-0.551), respectively. Fig 2a shows the Kaplan-Meier curve for 
HCC recurrence-free probability.  
In subjects without a history of HCC the cumulative hazards of HCC occurrence at 6, 
12 and 18 months were 0.010 (95% CI: 0.004-0.026), 0.050 (95% CI: 0.031-0.079) and 
0.072 (95% CI: 0.048-0.108), respectively. Fig. 2b shows the Kaplan-Meier curve for 
HCC occurrence-free probability. 
The median censoring time was 19.19 (1.12-26.41) for patients with a history of HCC 
and 18.23 months (1.84-24.41) for patients without a history of HCC. 
The median time to HCC from start of DAA treatment was 8.5 months (0.4-20.8) for 
patients with and 10.8 (0.9-20.1) for patients without a history of HCC. 
 
3.2 Predictors of HCC recurrence and occurrence 
Results from univariable Cox regression models for patients without a history of HCC 
are reported in Table 2. Based on univariable analysis, a 10-unit increase of AST (p = 
0.036, HR: 1.06, 95% CI: 1.01–1.12), a 1-unit increase of bilirubin (p = 0.035, HR: 
1.46, 95% CI: 1.03–2.08), a 10-unit increase of ALRI (p =0.002, HR: 1.07, 95% CI: 
1.02–1.11), and a 1-unit increase in ALBI score (p = 0.001, HR: 2.99, 95% CI: 1.45–
6.15) were significantly associated with a higher hazard of HCC occurrence. In 
addition, a 1-unit increase of albumin (p = 0.004, HR: 0.34, 95% CI: 0.17–0.71), and a 
10-unit increase of platelet count (p = 0.007, HR: 0.89, 95% CI: 0.82–0.97) were 
significantly associated with a decreased hazard of HCC occurrence. 
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At multivariable analysis, ALBI score (p = 0.038, HR: 2.35, 95% CI: 1.05–5.25) and the 
platelet count (p =0.048, HR: 0.92, 95% CI: 0.85–1.00) resulted independently 
associated with HCC occurrence. 
Based on this final multivariable model, a nomogram for predicting the HCC-free 
probability at 1-year of start of DAA treatment was built (Fig 3). 
At univariable analysis, applying the cut-off values published by Johnson et al [24] to 
ALBI grade, patients with ALBI grade 2 or 3 had a risk of HCC occurrence over three 
times higher than those with ALBI grade 1 (p = 0.01, HR: 3.22, 95% CI: 1.32-7.86). 
Using a cut-off value of 100 x 109/L for platelets, patients with platelets < 100 x109/L 
had about a two-fold higher risk of HCC occurrence than patients with platelets > 100 
x109/L (p = 0.033, HR: 2.15, 95% CI: 1.03-4.51). When the categorized variables for 
ALBI grade and platelets were both included in a multivariable model, ALBI grade 
resulted statistically significant (ALBI grade 2-3 vs ALBI grade 1: p = 0.01, HR: 2.71, 
95% CI: 1.08-6.83), while platelet count did not (platelets < 100 x109/L vs platelets > 
100 x109/L: p = 0.169, HR 1.70, 95% CI: 0.80-3.64). 
In patients with a history of HCC, only a 10-unit increase in ALRI index (p = 0.037 HR: 
1.03, 95% CI: 1.00–1.05) resulted significantly associated with HCC recurrence at 
univariable analysis. Neither AST (p = 0.243), nor bilirubin (p = 0.937), nor ALBI score 
(p = 0.405), nor albumin (p = 0.364), nor platelet count (p = 0.562) were associated with 
recurrence (Tab 3). Adjusting for the time from HCC treatment, ALRI index remained 
independently associated with the risk of HCC recurrence (p=0.007 HR: 1.05, 95% CI: 
1.01 – 1.09).  
 
3.3 Inflammatory parameters changes after treatment 
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At baseline, patients without a history of HCC had a higher number of neutrophils and 
lymphocytes than those with a history of HCC (neutrophils: 2.96 ± 1.33 vs 2.59 ± 1.10 
x109/L respectively; lymphocytes: 1.70 ± 0.85 vs 1.37 ± 0.77 x109/L, respectively).  As 
shown in Supplementary Table 1, baseline NLR, PLR and SII significantly increased 
and ALRI significantly decreased at the end of DAA treatment in patients without a 
history of HCC. Conversely, no changes were observed in patients with a history of 
HCC apart from ALRI that resulted significantly decreased. 
In patients without a history of HCC, a significant increase in neutrophil counts (2.96 ± 
1.33 vs 3.17 ± 1.47 x109/L, p=0,003) and a significant decrease in lymphocyte counts 
(1.70 ± 0.85 vs 1.47 ± 0.79 x109/L, p<0.001) were observed between baseline and the 
end of treatment. 
 
4. Discussion  
This study evaluated ALBI score and immune-inflammation parameters as potential 
predictors of HCC occurrence or recurrence in patients treated with DAA for chronic 
hepatitis C.  
The annual risk of HCC in untreated patients with HCV-related cirrhosis ranges 
between 3-5% [29] for those without a history of HCC, and 15-20% for patients with a 
history of HCC treated with surgical resection or radiofrequency ablation [30-40]. 
Some recent studies have shown unexpected high HCC recurrence rates after DAA 
therapy [2-4], but other studies contradicted these findings [5-9]. Given these 
contrasting data, it is pivotal to identify the patients at a higher risk and to determine the 
possible mechanisms associated with early occurrence or recurrence. 
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Our study considered a homogenous population of cirrhotic patients divided into two 
subgroups characterized by the presence of absence  of a history of HCC. We found that 
in patients without a history of HCC, the risk of HCC development seemed dependent 
on the stage of liver disease (as evidenced by the ALBI score and platelet count). Liver 
function impairment and cirrhosis remain the main predictors of the risk of HCC for 
these patients as well as for the untreated patients with hepatitis C [41]. 
Interestingly, our data show that pre-treatment liver stiffness was not associated with the 
prediction of the risk to develop HCC at univariate analysis, probably suggesting that 
liver dysfunction is a better predictor than the stage of liver fibrosis. 
Platelets are involved in thrombosis, inflammatory responses, liver regeneration [42-
44], and the regulation of angiogenesis [45]. Low platelet count in cirrhosis is 
associated with a higher risk of developing HCC representing an indirect marker of 
advanced disease [46].  
A nomogram was developed to predict the risk of HCC recurrence in this population at 
1 year. This graphical representation may help computing the patient’s risk of HCC 
within a specific timeframe and potentially planning differentiated follow-up schedules. 
For example, a patient without previous HCC with an ALBI score of -3 (ALBI grade 1 
category) and a platelet count of 150 x109/L would have a total of 95.5 points (ALBI 
grade = 12.5 points and platelets = 83 points). For a patient with these characteristics, 
the predicted probability of HCC recurrence in the first year of start of DAA therapy is 
0%. Conversely, for a patient with ALBI score of -1.40 (ALBI grade 2 category) and a 
platelet count of 50 x109/L would have a total of 127 points (ALBI grade = 32 points 
and platelets = 95 points) with a risk of recurrence HCC of about 20%. The nomogram 
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can be used to evaluate the HCC risk for each patient and plan a closer follow-up in 
high-risk patients. 
Hepatic function does not seem to predict the risk of cancer recurrence in patients with a 
history of HCC, although ALRI index seems to be a good predictor. One explanation 
could be that a dysregulation of the antitumor response after the sharp decrease in HCV 
viral load induced by DAA therapy may lead to tumor recurrence. Recurrence could be 
accelerated by DAA effects, boosting the growth of undetectable HCC as a consequence 
of a perturbation of the immune surveillance, caused by a swift clearance of HCV. 
ALRI index is an inflammation and immune-based prognostic score. Several studies 
have shown that ALRI index can predict therapy outcome in patients with HCC [14-16]. 
ALRI index can reflect the efficacy of the immune response based on lymphocytes and 
hepatic index aspartate aminotransferase.  
We reported different results in two different populations (patients without a history of 
HCC and patients with a history of HCC). The greater risk factor for the development of 
HCC in patients without a history of HCC is the severity of liver cirrhosis, similarly to 
the tpopulation no treated with DAA. Conversely, we believe that the immuno-related 
factor was the only predictor of occurrence in patients with a history of HCC because 
they may had already carried an immunologic switch that had promoted cancer 
development. 
Other interesting results of this study are the significant decrease in lymphocyte counts 
and the significant increase in neutrophils during DAA therapy. We think that this 
created a favorable microenvironment for the growth of a misinterpreted focus of cancer 
cells that had promoted HCC progression. Other markers tested in this study (NLR, 
PLR and SII) showed an increase during treatment with DAA. This imbalance reflects 
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an increase in the inflammatory state during treatment, allowing us to conclude that this 
change may underlie HCC occurrence and recurrence during DAA therapy. 
With this respect, a recent study by Villani et al. [47] demonstrated that DAA therapy 
induces a rapid reduction in TNF-α, IL-10, and induces an increase in serum VEGF. In 
particular, IL-10 is a immunoregulatory molecule involved in anti-inflammatory 
processes in chronic HCV infection. During persistent infections the virus exploits the 
production of IL-10 by dentritic cells (DCs) to exhaust antiviral T cells. High IL-10 
levels produced by DCs suppress their antigen presenting capacity and lead to 
inefficient T cell activation. Chronic antigen presence further exhausts T cells and 
induce IL-10 production. T cells therefore become tolerant to viral antigens and 
infection persists [48]. Moreover, IL-10 has pleiotropic and controversial functions in 
tumor biology, as it seems to function at the crossroads between immune stimulation 
and immune suppression in cancer [49]. For this reason evaluation of ALRI index 
allows to evaluate the patient's general inflammatory state and to predict which patients 
are at greater risk of relapse after DAA treatment. This hypothesis, however, needs to be 
supported in a specific translational trial. 
Among the limitations of this study is its retrospective nature, which might have 
precluded the collection of data on potential confounding factors or important 
prognostic factors. However, all cases were consecutively selected, thus reducing any 
potential bias. Missing data were imputed using multiple imputation, a method proven 
superior to single value imputation methods (i.e. mean imputation), and the complete 
case approach, which generally generates problems in case of missing at random data, 
with the effect of reducing the sample size, and in case of missing not at random data, 
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with the effect of producing biased estimates [28]. Finally, another limitation is the 
relatively short follow-up of patients. 
In conclusion, to our knowledge, this is the first study to have investigated the risk 
factors of HCC development after DAA treatment using immune inflammation 
indicators and ALBI score. Our results indicate that an impaired liver function, but not 
immune inflammation indicators, is an independent risk factor for the occurrence of 
HCC after DAA in patients without a history of HCC. On the contrary, the immune-
inflammation ALRI index seems to be an independent predictor of recurrence in 
patients with a history of HCC. Furthermore, we demonstrated that DAA therapy leads 
to an increase in neutrophils and a decrease in lymphocytes, resulting in a potential 
imbalance and a subsequent favorable microenvironment for the growth of cancer cells. 
Low cost, easy determination, and reproducibility of these markers could be usefully in 
clinical practice. Further studies in larger cohorts of patients are needed to confirm these 
results. 
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Figure legends 
Fig 1. Flow chart of the study population. 
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Fig 2. Kaplan-Meier curves for HCC-free probability among patients with a history of HCC (2a) 
and without a history of HCC (2b). 
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Fig 3. Nomogram for HCC-free probability at 12 months for patients without a history of HCC. 
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Table legends 
Table 1. Baseline characteristics of patients with and without a history of HCC.  
Baseline characteristics Without history of previous HCC 
(N=416) 
With history of previous HCC 
(N=98) 
P-value 
Male sex 242 (58.2%) 60 (61.2%) 0.581 
Age at start of therapy, years 63.3 [30.9 – 89.7]  71.0 [47.3 – 86.0] 
 
0.016 
Oesophageal varices 141 (51.8%) 46 (60.5%) 0.179 
Diabetes 96 (23.1%) 28 (28.6%) 0.253 
Child-Pugh 
A 
B 
 
351 (84.4) 
65 (13.1) 
 
72 (73.5) 
26 (26.5) 
 
 
0.004 
Arterial hypertension 210 (50.7%) 0,58 40 (40.8%) 0.078 
HBsAg positive 3 (0.7%) 1 (1.0%) 0.569 
HCV genotype: 
1a 
1b 
2 
3 
4 
 
53 (12.7%) 
240 (57.7%) 
45 (10.8%) 
61 (14.7%) 
17 (4.1%) 
 
10 (10.2%) 
57 (58.2%) 
10 (10.2%) 
12 (12.2%) 
9 (9.2%) 
 
 
 
0.303 
Antiviral treatment: 
SOF+SMV 
SOF+LDV 
SOF+DCV 
SOF+RBV 
Omb/Par/Rit+Das 
Omb/Par/Rit 
 
107 (25.7%) 
79 (19.0%) 
75 (18.0%) 
57 (13.7%) 
84 (20.2%) 
14 (3.4%) 
 
28 (28.6%) 
12 (12.2%) 
19 (19.4%) 
20 (20.4%) 
17 (17.4%) 
2 (2.0%) 
 
 
 
 
0.377 
Ribavirin use 303 (73.0%) 69 (70.4%) 0.604 
HCV RNA, IU/mL 961083 [504 – 23800000] 608178 [227 – 24400000] 0.172 
Time from HCC treatment 
(months) 
 
< 6      
6-12   
12-24   
>= 24 mesi  
  
34 (35.8%) 
17 (17.9%) 
25 (26.3%)  
19 (20.0%) 
 
 
Missing 1 3  
Stiffness 19.1 [5 – 70.6] 21.3 [5 – 58] 0.393 
Missing 84 32  
AST, IU/L 71 [16 – 344] 66 [11 – 206] 0.284 
Missing 66 17  
ALT, IU/L 65 [14 – 428] 57 [11 – 376] 0.172 
Missing 7 2  
Bilirubin, mg/dL 0.8 [0.2 – 5.9] 1.0 [0.3 – 3.8] 0.100 
Missing 4 1  
INR 1.1 [0.9 – 3.0] 1.1 [1.0 – 2.1] 0.341 
Missing 46 8  
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Albumin, g/dL 3.9 [2.1 – 5] 3.7 [2.1 – 4.9] 0.003 
Missing 22 6  
Creatinin, md/dL 0.8 [0.3 – 2.3] 0.8 [0.5 – 1.7] 0.092 
Missing 4 -  
Hemoglobin, g/dL 13.8 [8.2 – 18.3] 13.1 [8.8 – 17.8] 0.043 
Missing 9 3  
Neutrophils, x109/L 2.9 [0.6 – 10.1] 2.5 [0.3 – 5.8] 0.042 
Missing 28 3  
Lymphocytes, x109/L 1.7 [0.3 – 8.2] 1.3 [0.1 – 4.7] <0.001 
Missing 28 3  
Platelets, x109/L 114 [15 – 767] 95.5 [26 – 308] 0.006 
Missing 9 2  
NLR 1.8 [0.2 – 12.1] 2.1 [0.1 – 20.9] 0.064 
Missing 28 3  
PLR 73.2 [10.6 – 430.9] 76.3 [25.4 – 400] 0.819 
Missing 29 3  
SII 202.3 [29.0 – 1659.1] 207.3 [9.3 – 1385.2] 0.100 
Missing 29 3  
ALRI 46.5 [5.8 - 418.4] 64.2 [9.4 – 700] 0.005 
Missing 84 19  
ALBI -2.5 [-3.7 - -0.8] -2.4 [-3.3 - -0.7] 0.034 
Missing 22 7  
PALBI -2.6 [-3.5 - -1.1] -2.5 [-3.3 - -1.5] 0.401 
Missing 25 8  
Data are given as median [min-max] or as number of cases and percentage (%). 
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Table 2. Results from univariable and multivariable Cox regression for the time to HCC 
occurrence in patients without a history HCC. 
 
 Univariate analysis Multivariate analysis 
  HR (95% CI) P-value 
HR (95% 
CI) 
P-value 
Sex (ref. Male) 0.61 0.28 – 1.35 0.225    
Age at start of therapy, 
years 1.02 0.99-1.05 0.262 
   
Varices (ref. No) 1.60 0.75-3.41 0.221    
Child-Pugh (ref. A) 
B 1.72 0.69-4.23 0.242 
   
Diabetes (ref. No) 0.77 0.29-2.03 0.602    
Hypertension (ref. No) 0.66 0.32-1.38 0.271    
AST‡ 1.06 1.01-1.12 0.036    
ALT‡ 1.03 0.97-1.09 0.402    
Bilirubin 1.46 1.03-2.08 0.035    
INR  1.54 0.27-8.70 0.625    
Albumin 0.34 0.17-0.71 0.004    
Creatinine 0.87 0.14-5.39 0.879    
Hemoglobin 0.88 0.73-1.07 0.216    
Neutrophil 0.76 0.54-1.07 0.119    
Lymphocyte 0.58 0.33-1.01 0.056    
Platelet‡ 0.89 0.82-0.97 0.007 
0.92 0.85-
1.00 
0.048 
NLR 1.05 0.81-1.37 0.689    
PLR‡ 0.93 0.84-1.04 0.226    
SII‡ 0.98 0.95-1.01 0.200    
Liver Stiffness  1.02 0.99-1.05 0.213    
ALRI‡ 1.07 1.02-1.11 0.002    
ALBI 2.99 1.45-6.15 0.003 
2.35 1.05-
5.25 
0.038 
PALBI 2.06 0.79-5.42 0.142    
SVR  3.1 0.98-9.8 0.054    
‡Reported as a 10-unit increase 
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Table 3. Results from univariable Cox regression for the time to HCC recurrence in 
patients with a history of HCC. 
 Univariable analysis Multivariate analysis 
  HR  (95% CI) P-value 
HR (95% 
CI) 
P-value 
Sex (ref. male) 1.39  0.68 – 2.85  0.370    
Age at start of therapy, 
years 0.99  0.96-1.03 0.764  
   
Esophageal varices (ref. 
No) 0.75 0.36-1.55  0.430  
   
Child-Pugh (ref. A) 
B 
 
0.60 0.23-1.58 0.300 
   
Diabetes (ref. No)  1.17 0.54-2.56  0.691     
Ipertension (ref. No) 0.99 0.48-2.05  0.971     
Ast‡ 1.00 0.91-1.11 0.243    
Alt‡ 1.04 0.97-1.11 0.391    
Bilirubin 0.98 0.59-1.64 0.937    
INR  1.37 0.19-10.07 0.757    
Albumin 0.70 0.33-1.48 0.346    
Creatinine 1.33 0.26-6.89 0.730    
Hemoglobin 1.06 0.88-1.29 0.521    
Neutrophil 0.89 0.62-1.27 0.512    
Lymphocyte 0.83 0.48-1.43 0.496    
Platelet‡ 0.98  0.91-1.05 0.562    
NLR 1.09 0.99-1.19 0.092    
PLR‡ 1.01 0.96-1.07 0.616    
SII‡ 1.01 0.99-1.02 0.405    
Stiffness  1.02 0.99-1.04 0.264    
ALRI‡ 1.03 1.00-1.05 0.037 1.05 1.01-1.09 0.008 
ALBI 1.35 0.66-2.77 0.405    
PALBI 1.31 0.48-3.57 0.600    
SVR 0.83 0.21-3.39 0.799    
Time from HCC (months) 
<6 
6-12 
12-24 
>=24 
 
1 
0.48  
1.29 
0.30 
 
0.14-1.67  
  0.58-2.87 
  0.07-1.33 
 
0.248 
0.532 
0.112 
 
 
1 
0.40 
1.42 
0.17 
 
 
0.11-1.44 
0.63-3.16 
0.02-1.16 
 
 
 
0.160 
0.395 
0.070 
‡Reported as a 10-unit increase 
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